Windtree's Latest Advances: Istaroxime Clinical Trials
Windtree Therapeutics Updates Istaroxime Clinical Development and Trial Data Providing a thorough update on the clinical and business development of istaroxime, Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company committed to developing creative therapies for critical diseases, has This first-in-class treatment seeks to raise blood pressure, preserve or increase renal function, and strengthen systolic contraction and diastolic relaxation of the heart. In three Ph
Continue Reading